Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of March 6, 2023
In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more.
Read the full coverage here:
Neoadjuvant nivolumab confers durable survival benefit in resectable NSCLC
Global economic cost of cancer estimated to exceed $25 trillion over 30 years
Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints
Researchers develop AI model to accelerate radiation therapy planning for lung cancer
Asian, Black patients with lung cancer face longer wait times to radiation treatment
References:
Chen S, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2022.7826.
Hosny A, et al. Lancet Digit Health. 2022;doi:10.1016/S2589-7500(22)00129-7.
Press Release
Rekulapelli A, et al. Health Equity. 2022;doi:10.1089/heq.2022.0104
Rosner S, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2994.
Collapse
